[28] MC, S., et al. Association of Delayed Adjuvant Chemotherapy With Survival After Lung Cancer Surgery[J]. JAMA oncology, 2017,3(5):610-619.

[29] 杨路,徐海燕,王燕.新型冠状病毒肺炎疫情期间肺癌患者的内科诊疗策略[J].中华肿瘤杂志,2020(04):292-293-294-295.

[30] WZ, Z., et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC(ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study[J]. The Lancet. Oncology, 2018,19(1):139-148.

[31] 陈良安.呼吸道传染病--新型冠状病毒肺炎流行期间晚期非小细胞肺癌患者诊疗专家指引（试行）[J].中华结核和呼吸杂志, 2020. 43(4):297-301.

[32] H, Z., H. Y, and X. C.The Treatment and Outcome of a Lung Cancer Patient Infected with SARS-CoV-2[J]. Journal of thoracic oncology, 2020.

[33] Yang S , Zhang Z , Wang Q . Emerging therapies for small cell lung cancer[J]. Journal of Hematology & Oncology, 2019, 12(1).

[34] 刘斌亮,马飞,王佳妮,等.新型冠状病毒肺炎疫情期间乳腺癌患者的院外管理[J].中华肿瘤杂志,2020(04):288-289-290-291.

[35] R, S. and K. stem cell transplantation dilemma during the COVID-19 era[J]. Future oncology (London, England), 2020.

[36] KK, S., et al. Facing COVID-19 in the hematopoietic cell transplant setting: A new challenge for transplantation physicians[J].Blood cells, molecules & diseases, 2020,83:.

文章来源：《肿瘤药学》 网址: http://www.zlyxzz.cn/qikandaodu/2021/0510/1207.html